Literature DB >> 11853117

Calcitonin gene-related peptide and calcitonin in the CSF of patients with dementia and depression: possible disease markers.

Aleksander A Mathé1, Hans Agren, Anders Wallin, Kaj Blennow.   

Abstract

Cerebrospinal fluid (CSF) was obtained from 32 patients with dementia, 19 healthy controls that were age-matched with the dementia patients, and 29 DSM-IV major depression patients and calcitonin gene-related peptide-like immunoreactivity (CGRP-LI) and calcitonin-like immunoreactivity (CT-LI) measured by RIA. CGRP-LI was lower in the dementia group compared to both the controls and depressed patients (P<.01) after covarying out sex and age. CT-LI was decreased in the dementia and depressed patients (P<.05) compared to the controls. A positive relationship between CGRP-LI and CT-LI was found in dementia. A logistic discriminant analysis with calcitonin gene-related peptide (CGRP) and log calcitonin (CT) predicting diagnosis (three classes) revealed a significant overall fit (chi2 = 18.08, P = .0011), with an effect test showing contributions of both independent variables: CGRP (chi2 = 10.03, P<.007), log CT (chi2 = 8.63, P = .013). In dementia, both CGRP-LI and CT-LI were decreased and their concentration ratio did not differ from that in controls, likely reflecting a general neuronal loss. Alternatively and more speculatively, but theoretically possible, expression of the alpha-CGRP/CT gene may be affected in dementia. In contrast, in depression, CT-LI but not CGRP-LI was decreased and the CGRP/CT concentration ratio was increased, which is consistent with a possibility of an altered splicing process favoring CGRP mRNA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11853117     DOI: 10.1016/s0278-5846(01)00219-6

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Cerebrospinal Fluid α-Calcitonin Gene-Related Peptide: A Comparison between Alzheimer's Disease and Multiple Sclerosis.

Authors:  Giulio Papiri; Arianna Vignini; Luigi Capriotti; Paola Verdenelli; Sonila Alia; Alice Di Paolo; Chiara Fiori; Sara Baldinelli; Mauro Silvestrini; Simona Luzzi
Journal:  Biomolecules       Date:  2022-01-24

2.  Role of central calcitonin gene-related peptide (CGRP) in locomotor and anxiety- and depression-like behaviors in two mouse strains exhibiting a CGRP-dependent difference in thermal pain sensitivity.

Authors:  Ara Schorscher-Petcu; Jean-Sébastien Austin; Jeffrey S Mogil; Rémi Quirion
Journal:  J Mol Neurosci       Date:  2009-04-18       Impact factor: 3.444

3.  Endogenous calcitonin gene-related peptide in cerebrospinal fluid and early quality of life and mental health after good-grade spontaneous subarachnoid hemorrhage-a feasibility series.

Authors:  Elisabeth Bründl; Martin Proescholdt; Eva-Maria Störr; Petra Schödel; Sylvia Bele; Julius Höhne; Florian Zeman; Alexander Brawanski; Karl-Michael Schebesch
Journal:  Neurosurg Rev       Date:  2020-06-22       Impact factor: 3.042

4.  Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder.

Authors:  Per Svenningsson; Sven Pålhagen; Aleksander A Mathé
Journal:  Front Psychiatry       Date:  2017-06-12       Impact factor: 4.157

5.  Salmon Calcitonin Exerts an Antidepressant Effect by Activating Amylin Receptors.

Authors:  Jian Jiang; Jun Ju; Liang Luo; Ze Song; Huanquan Liao; Xiuyan Yang; Shoupeng Wei; Dilong Wang; Wenhui Zhu; Jinlong Chang; Junzhe Ma; Hao Hu; Jiezhong Yu; Huiqing Wang; Sheng-Tao Hou; Shupeng Li; Huiliang Li; Ningning Li
Journal:  Front Pharmacol       Date:  2022-02-14       Impact factor: 5.810

6.  Gestational environment programs adult depression-like behavior through methylation of the calcitonin gene-related peptide gene.

Authors:  J Jiao; M D Opal; S C Dulawa
Journal:  Mol Psychiatry       Date:  2012-10-09       Impact factor: 15.992

7.  Comparison of beta-endorphin and CGRP levels before and after treatment for severe schizophrenia.

Authors:  Małgorzata Urban-Kowalczyk; Janusz Śmigielski; Dominik Strzelecki
Journal:  Neuropsychiatr Dis Treat       Date:  2016-04-15       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.